-
Action Advances Fight Against COVID-19, Follows Comprehensive Evaluation of Available Safety, Effectiveness and Manufacturing Quality Information by FDA Career Scientists, Input from External Experts
Author Archive: AZBio
HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology
TUCSON, Ariz., Feb. 26, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed its feasibility testing for a planned whole transcriptome panel using the HTG EdgeSeq technology, and has released a follow-on whole transcriptome product white paper (White Paper Two), regarding the performance of a prototype panel for multiple cancer indications compared to RNA sequencing (RNA-Seq). HTG is developing a whole transcriptome panel using the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned research use only launch in the third quarter of 2021.Continue reading
Seven Arizona bio startups earn $30K through Flinn entrepreneurship program
Five Phoenix, two Tucson firms to receive personalized learning plan, other benefitsContinue reading
VectorCare and Life365 align to expand and accelerate the deployment of digital health solutions for healthcare organizations
The joint partnership between Life365 and VectorCare will enable healthcare organizations to create more efficient workflows and accelerate the deployment of digital health solutions. The companies saw an opportunity to provide remote health monitoring services to effectively treat and manage patients in their homes.
TGen-Led Study Confirms Cell-Free DNA in Urine as Potential Method for Cancer Detection
If successful, non-invasive method could transform detection and treatment outcomesContinue reading
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope’s Genomic Institute, TGen
Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders
Arizona Board of Regents announces José Luis Cruz as Northern Arizona University presidential finalist
The Arizona Board of Regents announced today that José Luis Cruz, Ph.D. is the finalist for the position of the 17th president of Northern Arizona University.Continue reading
UArizona Startup GenetiRate Acquired by Aquaculture Biotechnology Company
TUCSON, Ariz. – University of Arizona startup GenetiRate has been acquired by biotechnology company IMV Technologies.Continue reading
AZBio Elects 2020 Officers and Welcomes New Board Members
The Arizona Bioindustry Association, Inc. (AZBio) Board of Directors has elected its 2021 officers and welcomes seven new board members in 2021. Continue reading
eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients
TUCSON, AZ / ACCESSWIRE / February 11, 2021 / Several recent publications have now highlighted the involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in the pathobiology of SARS-CoV-2 infection.